Compare DexCom, Inc. (DXCM) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Global X NASDAQ 100 Covered Call ETF — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Global X NASDAQ 100 Covered Call ETF trades at $18.69 (market cap $8.49B). The key difference: DexCom, Inc. is far larger — about 3.8× Global X NASDAQ 100 Covered Call ETF's market cap, and Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Global X NASDAQ 100 Covered Call ETF for 51 Days on average.
| DXCM | QYLD | |
|---|---|---|
Market Cap | $31.86B | $8.49B |
Volume | 3,607,070 | 2,913,938 |
Sector | Health | Income / Options Overlay |
52-Week High | $92.34 | $18.69 |
52-Week Low | $54.84 | $16.70 |
Typical Hold Time | 62 Days | 51 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
QYLD trades at $18.66, showing minimal daily movement with a slight decline of -0.11%. The ETF maintains a consistent monthly dividend distribution of $0.18 per share, with technical indicators showing mixed signals—bullish moving averages but bearish oscillators including overbought RSI readings. Recent news highlights QYLD's high yield strategy but raises concerns about long-term capital erosion and tax implications.
QYLD offers high monthly income through covered call strategies but faces significant risks from capped upside potential and principal erosion. The ETF's distribution sustainability depends on Nasdaq volatility, with recent articles warning about declining option premiums. Investors should weigh the trade-off between immediate income and long-term capital preservation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
